Skip to content

Cardiac Surgery: In Vivo Titration of Protamine

Cardiac Surgery : In Vivo Titration of Protamine

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00684450
Acronym
Protamine
Enrollment
138
Registered
2008-05-26
Start date
2008-06-30
Completion date
2011-06-30
Last updated
2011-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bleeding

Keywords

titration of protamine, exact dose, protamine, neutralize heparin

Brief summary

Safe use of cardiopulmonary bypass (CPB) requires massive doses of intravenous unfractionated heparin. At end-CPB, residual heparin is neutralized with intravenous injection of protamine sulfate. This prospective, randomized, controlled study will be conducted in 82 voluntary subjects admitted for elective, first intention, cardiac surgery requiring cardiopulmonary bypass. Each will be randomly assigned to one of two groups. The control group will be submitted to a standard protamine infusion of 1.3mg :100U of the total heparin dose given during bypass. The test group will receive an infusion of protamine (over 15 minutes) until activated clotting time (ACT) values (determined every 3 minutes) depict a plateau, sign that the optimal protamine to heparin ratio has been attained. The investigators hypothesize this new in vivo titration method to be as efficient as the standard protocol (adequacy of heparin neutralization, % heparin rebound, bleeding, and transfusion), and potentially safer by its ability to prevent protamine overdose and its deleterious impact on platelet function.15 Principal Objective Evaluate a new in vivo method of titration of protamine sulfate. Secondary Objective Evaluate the impact of this method on the adequacy of heparin neutralization by measuring: 1. platelet count 2. postoperative bleeding 3. transfusion exposure a 4. incidence of heparin rebound

Detailed description

Protamine sulfate is administered to reverse the anticoagulant effects of heparin upon completion of cardiopulmonary bypass (CPB). In most cases, protamine is given in amounts sufficient to neutralize the total dose of heparin.9 This dose is usually calculated with a ratio of 1.3mg protamine for every 100U heparin given.10 In the literature, reported doses of intraoperatively administered protamine range from 0 to 8mg per 100U of heparin. Given in excess, protamine can, in addition to complement activation and hemodynamic instability,11 induce platelet dysfunctions.12-16 The latter significantly increases both the cost and morbidity of cardiac interventions as it is one of the main causes of postoperative bleeding. The optimal protamine/heparin ratio is difficult to individualize for each patient because of the great interpatient variability in heparin's metabolism4-7 and of the absence of correlation between ACT and heparin's plasma concentration.8 Consumption of heparin may vary from 0.01 to 3.86U/Kg per minute during CPB.30 The exact concentration of remaining circulating heparin at the end of bypass is not easily obtained.

Interventions

PROCEDURETitration protamine

10\. Study group: celite ACT will be performed every 3 minutes during protamine infusion until ACT values suggest reach of a plateau (defined as 2 similar ACT values, within 10% variability, and ACT ≤ to 160 seconds.), time at which infusion will be stopped. 2cc of blood is required per ACT test, for a maximum total of 10cc.

DRUGStandard administration of protamine

1.3 mg of Protamine for 100u héparine

Sponsors

Organon
CollaboratorINDUSTRY
Montreal Heart Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* First intention, elective, cardiac surgery: either Coronary Artery Bypass Graft (CABG)or valve repair/replacement. * Patients on preoperative aspirin, clopidogrel or heparin will be included.

Exclusion criteria

* Combination of CABG and valve surgery * Second intention cardiac surgery * ASA 5 patients * Pre-existing hemostatic disorder (as evidenced by history) * Pregnancy * PLavix \< 5 days before de surgery

Design outcomes

Primary

MeasureTime frame
Effective heparin neutralization (anti-Xa < 0.3 U/ml)Pre protamine, 15 min post protamine, 3h post protamine

Secondary

MeasureTime frame
Frequency of heparin rebound15 min post protamine and 3 hours post Protamine
Blood losses after surgery and transfusion requirementsdischarge
Preservation of the platelet countPre operate, Pré Protamine, 15 min post Protamine, 3 hours post Protamine

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026